Teleflex Incorporated — FY2014 Form 10-K
Reporting period: Fiscal year ended December 31, 2014. This is an annual filing, not a standalone fourth-quarter report. Teleflex is a global medical-device company focused primarily on single-use products for critical care and surgical procedures.
Financial performance and liquidity
| Metric | FY2014 | FY2013 |
|---|---|---|
| Revenue | $1,839.8 million | $1,696.3 million |
| Gross profit / gross margin | $942.4 million / 51.2% | $838.9 million / 49.5% |
| Income from continuing operations | $191.5 million | $152.2 million |
| Net income attributable to common shareholders | $187.7 million | $150.9 million |
| Diluted EPS | $4.04 net income; $4.10 continuing operations | $3.45 net income; $3.46 continuing operations |
| Operating cash flow from continuing operations | $290.2 million | $231.3 million |
| Capital expenditures / free cash flow | $67.6 million / $222.7 million | $63.6 million / $167.7 million |
| Cash and cash equivalents at year-end | $303.2 million | $432.0 million |
| Total assets / shareholders’ equity | $3,977.3 million / $1,911.3 million | $4,209.0 million / $1,913.5 million |
Revenue increased 8.5%. Management attributed the increase mainly to acquisitions ($98.6 million of revenue), price increases ($23.9 million), new products ($14.8 million) and higher volume ($12.3 million); foreign exchange reduced revenue by $6.2 million. Gross margin improved 170 basis points, while SG&A rose to $578.7 million, or 31.5% of revenue, from 29.6%. Operating income before interest, debt-extinguishment losses and taxes was $284.9 million, a 15.5% margin.
Year-end current assets were $1,053.2 million and current liabilities were $634.9 million. Debt principal totaled approximately $1,104.6 million, including $399.9 million of convertible notes classified as current; net debt was $801.4 million and net debt to total capital was 30%. The company reported compliance with its debt covenants; its leverage ratio was 2.71x and interest coverage ratio was 8.31x. The filing states management expected available cash, operating cash flow, credit facilities and receivables securitization capacity to cover foreseeable requirements.
For the fourth quarter, revenue was $476.0 million versus $450.5 million in Q4 2013. Income from continuing operations was $52.1 million and diluted net EPS was $1.07, compared with $35.3 million and $0.77, respectively, in the prior-year quarter.
Material changes and segment performance
- Revenue growth was substantially acquisition-supported. The 2014 acquisitions of Mayo Healthcare and Mini-Lap had aggregate estimated consideration of $66.3 million; 2013 acquisitions included Vidacare and Ultimate. The company also issued $250 million of 5.25% notes due 2024 and used net proceeds mainly to repay revolving-credit borrowings.
- Gross-margin gains reflected acquired and new higher-margin products, pricing and operating improvements, partly offset by higher raw-material and manufacturing costs and foreign exchange.
- EMEA revenue rose 6.4% to $593.1 million and operating profit rose 30.4% to $114.7 million. Asia revenue rose 14.7% to $237.7 million, but operating profit declined 2.6% to $62.2 million. Anesthesia/Respiratory North America revenue fell 2.6%; Vascular North America revenue increased 12.2%.
- Operating cash flow increased $58.9 million, supported by improved results, working-capital movements and lower domestic pension contributions. Cash declined by $128.7 million during the year, including a $19.5 million adverse exchange-rate effect; financing cash outflows included $480.1 million of debt repayments and $56.3 million of dividends.
- Consolidated net income rose, while comprehensive income fell to $38.6 million from $172.7 million, principally reflecting foreign-currency translation and pension-related losses recorded in other comprehensive income.
- The 2012 comparison period included a $332.1 million goodwill impairment charge; no goodwill impairment was recorded in 2014 or 2013. FY2014 also included $17.9 million of restructuring and other impairment charges.
Outlook, commentary, risks and unusual items
- No consolidated revenue or EPS guidance is provided in the supplied filing text. Management expected the manufacturing-footprint program to begin generating savings in 2015, with annualized savings of $28–$35 million when fully implemented; it estimated $37–$44 million in total pretax charges and completion by the end of 2017. Other 2014 restructuring programs were expected to yield additional annual savings: $8–$9 million in Europe and $4–$5 million from other programs, generally by the end of 2015.
- Management cited slower distributor sales to third parties in China and monitored distributor inventory; it also highlighted continued payment delays and credit risk in Italy, Spain, Portugal and Greece. Receivables from those countries were $76.2 million at year-end, equal to 27.3% of total net current and long-term receivables.
- The FDA issued a March 2014 warning letter concerning quality-system issues at the Arlington Heights, Illinois facility. Teleflex reported corrective actions were underway; further FDA enforcement remained possible until corrective actions were accepted and verified.
- A jury awarded $23 million in punitive damages, plus interest, in a product-liability case involving a former marine business. Teleflex was pursuing post-trial relief and intended to appeal if necessary; it stated amounts above $10 million were expected to be covered by insurance. The company had accrued its best estimate of probable loss.
- Teleflex identified substantial indebtedness, refinancing and conversion liquidity, acquisition integration, restructuring execution, product liability and recalls, regulatory compliance, reimbursement and pricing pressure, foreign exchange, commodity costs, and international operations as risks. The stock-price conversion condition made the $400 million 2017 convertible notes currently convertible at year-end; the company elected cash settlement of principal and shares for excess conversion value.
- The company reported approximately $41 million of Semprus in-process research and development assets and cautioned that commercialization challenges remained, creating possible future impairment risk. It also reported $33.4 million of contingent-consideration liabilities, with undiscounted potential payments ranging from $15 million to $83 million.
Important facts for investors to verify
- Separate acquisition-driven growth from organic growth, and assess whether pricing and new-product gains can offset weaker volumes in certain businesses.
- Review segment trends, particularly Asia’s profit decline and the reported distributor inventory concerns in China.
- Assess conversion, repayment and dilution scenarios for the $399.9 million convertible notes, including the effects of the note hedges and warrants.
- Track collections and allowance adequacy for European public-healthcare receivables, along with cash held at foreign subsidiaries and repatriation considerations.
- Monitor FDA remediation at Arlington Heights, restructuring costs and realized savings, the marine-business litigation outcome and Semprus commercialization progress.